Rare
lephants
Screener
Toggle theme
Halozyme Therapeutics, Inc.
HALO
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2017
Total Cash from Operations:
$651.6M
Line Item
Value
% of Total
Capital Expenditures
$0
0.0%
Business Acquisitions
$0
0.0%
Stock Repurchases
$207.5M
31.8%
Other
$423.5M
65.0%
Net Cash Flow
$20.6M
3.2%
Download CSV
